Fortrea Holdings (FTRE) Cash from Operations (2022 - 2026)
Fortrea Holdings (FTRE) posted Cash from Operations of 17000000.0 for Q1 2026, down 113.17% on a QoQ basis from 129100000.0 in Q4 2025, and up 86.31% year-over-year from 9124459.81 in Q1 2025.
Fortrea Holdings (FTRE) Cash from Operations (2022 - 2026) Analysis & Trends
Fortrea Holdings' Cash from Operations history runs 5 years deep, the most recent figure standing at 17000000.0 for Q1 2026.
- Quarterly Cash from Operations rose 86.31% year-over-year to 17000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 220700000.0 (up 34.41% YoY) and the FY2025 annual result came in at 113500000.0, down 56.81% from the prior year.
- Cash from Operations was 17000000.0 for Q1 2026 at Fortrea Holdings, down from 129100000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 273700000.0 in Q2 2024 and bottomed at 124200000.0 in Q1 2025.
- A 5-year average of 42140000.0 and a median of 18400000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations plunged 1180.0% — and 2025, when it surged 3716.67%.
- Fortrea Holdings' Cash from Operations stood at 23500000.0 in 2022, then decreased by 21.7% to 18400000.0 in 2023, then dropped by 7.07% to 17100000.0 in 2024, then jumped by 654.97% to 129100000.0 in 2025, then sank by 113.17% to 17000000.0 in 2026.
- Business Quant data shows FTRE's Cash from Operations at 17000000.0 in Q1 2026, 129100000.0 in Q4 2025, and 86800000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | -17.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.00 Mn |
| Mar 31, 2026 | -17.00 Mn |
| Dec 31, 2025 | 129.10 Mn |
| Dec 31, 2025 | 129.10 Mn |
| Sep 30, 2025 | 86.80 Mn |
| Sep 30, 2025 | 86.80 Mn |
| Jun 30, 2025 | 21.80 Mn |
| Jun 30, 2025 | 21.80 Mn |
| Mar 31, 2025 | -124.20 Mn |
| Mar 31, 2025 | -124.20 Mn |
| Dec 31, 2024 | 17.10 Mn |
| Dec 31, 2024 | 17.10 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Jun 30, 2024 | 273.70 Mn |
| Jun 30, 2024 | 273.70 Mn |
| Mar 31, 2024 | -25.60 Mn |
| Mar 31, 2024 | -25.60 Mn |
| Dec 31, 2023 | 18.40 Mn |
| Dec 31, 2023 | 18.40 Mn |